US20020176858A1 - Monoclonal antibodies to TGF-BETA - Google Patents
Monoclonal antibodies to TGF-BETA Download PDFInfo
- Publication number
- US20020176858A1 US20020176858A1 US10/173,074 US17307402A US2002176858A1 US 20020176858 A1 US20020176858 A1 US 20020176858A1 US 17307402 A US17307402 A US 17307402A US 2002176858 A1 US2002176858 A1 US 2002176858A1
- Authority
- US
- United States
- Prior art keywords
- tgf
- monoclonal antibody
- antibody
- binding
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
Definitions
- the present invention relates to the field of immunology and particularly to monoclonal antibodies specific to transforming growth factor beta (TGF-B) and applications thereof.
- TGF-B transforming growth factor beta
- TGF-B Transforming growth factor beta
- TGF-B1 and TGF-B2 are, in general, multifunctional cytokines that have potent inhibitory effects on the proliferation and effector responses of mitogen-, lymphokine-, and alloantigen-activated lymphocytes (Kearl et al, J Exp Med (1986) 163:1037; Ellingsworth et al, Cell Immunol (1988) 113: in press; Kearl et al, J Immunol (1986) 137:3855; Ranges et al, J Exp Med (1987) 166:991).
- TGF-B1 and TGF-B2 affect the proliferation and differentiation of other cells of the immune system including macrophages (Wall et al, Proc Natl Acad Sci USA (1987) 84:5788), pre-B cells (Lee et al, J Exp Med (1987) 166:1290), hematopoietic stem cells (Ohta et al, Nature (1987) 329:539; Ishibashi et al, Blood (1987) 69:1737; Keller et al, J Exp Med (1988) in press; Sing et al, Blood (1988) in press), and NK cells (Rook et al, J Immunol (1986) 136:3916).
- TGF-B1 The human sequence of TGF-B1 is identical to the bovine and porcine sequences and differs from the murine sequence by one amino acid. TGF-B1 is a dimer composed of two identical disulfide-linked chains of 112 amino acid residues.
- TGF-B2 is also a dimeric polypeptide and is disclosed in U.S. Pat. No. 4,774,322, filed Dec. 10, 1987, assigned to Collagen Corporation. Even though there are 14 amino acid differences in the first 36 amino acids residues of the two forms, their biological activities are similar (Cheifetz et al, Cell (1987) 48:409-415; Seyedin et al, J Biol Chem (1987) 262:1946-1949).
- TGF-B Antibodies to TGF-B are needed to investigate the varied biological actions of TGF-B, to study TGF-B biosynthesis, and to determine differences in activity or effect, if any, between the forms of TGF-B. These antibodies would also have therapeutic applications for treating indications where there is an overproduction of TGF-B (e.g., acute liver injury, chronic hepatic fibrosis) and for diagnosing or treating malignancies (e.g., sarcomas and melanomas) and metastatic cancers.
- TGF-B e.g., acute liver injury, chronic hepatic fibrosis
- malignancies e.g., sarcomas and melanomas
- the present invention provides a monoclonal antibody immunoreactive with TGF-B.
- a monoclonal antibody is described herein that is specific for TGF-B. This antibody, in preferred embodiments, binds to a neutralizing epitope on TGF-B or binds to an epitope on TGF-B which blocks the binding of TGF-B to its cellular receptors.
- Another aspect of the invention is to provide a stable cell line which secretes a monoclonal antibody specific for TGF-B.
- the cell line secretes a murine monoclonal antibody specific for TGF-B that has TGF-B neutralizing activity.
- Another aspect of the invention is a method for treating acute and chronic disease states that result from an overproduction of TGF-B, by administering a therapeutically effective amount of a monoclonal antibody reactive with TGF-B, or an antigen-binding fragment of a monoclonal antibody reactive with TGF-B.
- Another aspect of the invention is a method for treating tumor cells that produce TGF-B, by administering a therapeutically effective amount of a monoclonal antibody reactive with TGF-B to suppress the immunosuppressive effects of TGF-B.
- Another aspect of the invention is a method for treating metastatic cancers by administering a therapeutically effective amount of a monoclonal antibody reactive with TGF-B to mark tumor cells for destruction by complement or by immune cells dedicated to tumor cell removal
- a capture-ELISA for diagnosing disease states such as cancer and connective tissue (fibrotic) disorders comprising: coating a first monoclonal or polyclonal antibody reactive with TGF-B onto a surface, adding a sample containing an unknown amount of TGF-B or a standard concentration of purified TGF-B to the surface, adding polyclonal sera reactive with TGF-B or a monoclonal antibody of the invention to the surface, adding an enzyme-linked tertiary antibody (reactive to said monoclonal or polyclonal antibody), and determining the presence of TGF-B by quantifying the amount of enzymatic label present in a colorimetric reaction.
- CELISA capture-ELISA
- Another aspect of the invention is a chimeric monoclonal antibody, having an antigen-binding portion derived from the MAb of the invention, and the remainder derived from human antibodies.
- Such chimeric antibodies are described by S. L. Morrison, Science (1985) 229:1202.
- Another aspect of the invention is an anti-idio-typic antibody reactive with the MAbs of the invention, which are useful as TGF-B mimics. These mimics are capable of binding to TGF-B receptors, and thus may act as TGF-B agonists or antagonists.
- FIG. 1 is a Western blot of monoclonal antibodies binding to purified TGF-B2. Lanes 1-6 and 7-12 contain TGF-B2 run under non-reducing and reducing conditions, respectively.
- FIG. 2 illustrates the neutralization of TGF-B2 activity by the 1D11.16 MAb.
- FIG. 3 represents an autoradiogram showing inhibition of affinity cross-linked cell receptors from both thymocytes and the NRK cell line by MAbs.
- FIG. 4 illustrates the immunoprecipitation of [ 125 I]-labeled TGF-B2.
- FIG. 5 is a Western blot of monoclonal antibody 1D11.16 binding to purified TGF-B1 and TGF-B2. Lanes 2-5 and 6-9 contain various amounts of TGF-B2 and TGF-B1, respectively, run under non-reducing conditions.
- the present invention is directed broadly to the production of TGF-B monoclonal antibodies, neutralizing TGF-B antibodies and TGF-B antibodies that block the binding of TGF-B to cellular receptors.
- the present invention is also directed to the use of such antibodies in diagnostic assays to determine elevated levels of TGF-B that are associated with certain disease states, and in therapeutic applications to prevent the overproduction of TGF-B or to suppress the immunosuppressive effects of TGF-B in tumor cells.
- the terms “monoclonal antibody” and “MAb” refer to an immunoglobulin composition having a substantially homogenous population of antibodies, each of which binds to the same antigenic determinant Unless otherwise indicated, the term is not intended to be limited to antibodies of any particular mammalian species or isotype, or to antibodies prepared in any given manner. The term is intended to include whole antibody molecules as well as antigen-binding fragments (e.g., Fab′, F(ab′) 2 ).
- Cell line refers to various embodiments including but not limited to individual cells, harvested cells, and cultures containing cells so long as they are derived from cells of the cell line referred to.
- the terms “permanent” and “stable” mean that the lines remain viable over a period of time, typically at least about six months, and maintain the ability to produce the specified monoclonal antibody through at least about 50 passages.
- TGF-B refers in general to the family of transforming growth factors (beta-chain) which participate in the control of cell proliferation and differentiation. As used herein the term refers to both TGF-B1 and TGF-B2 proteins.
- Other known TGF-B-like proteins are the “inhibins” (Mason et al, Nature (1985) 318:659-663), their beta-chain dimers, “activins” (Ling et al, Nature (1986) 321:779-782; Vale et al, Nature (1986) 321:776-779), Mullerian inhibiting substance (Cate et al, Cell (1986) 45:685-698) and a predicted protein product of the decapentaplegic gene complex of Drosophila (Padgett et al, Nature (1987) 325:81-84) as shown by complementary DNA sequence analysis.
- An antibody that “is reactive with” or “specific to” TGF-B is an antibody that binds an epitope present on TGF-B.
- An antibody that “neutralizes in vitro biological activity of TGF-B” when bound to its epitope on TGF-B is defined by testing the antibody-bound TGF-B in an in vitro assay such as the IL-1 and PHA-dependent thymocyte proliferation assay, the NRK proliferation assay or an assay using the ROS 17.2.8 osteosarcoma cell line, all of which are described in the following examples.
- an in vitro assay such as the IL-1 and PHA-dependent thymocyte proliferation assay, the NRK proliferation assay or an assay using the ROS 17.2.8 osteosarcoma cell line, all of which are described in the following examples.
- An antibody that “blocks binding to cellular receptors” of TGF-B is an antibody that blocks the binding of TGF-B to TGF-B cellular receptors in a standard receptor binding assay, such as the one described in the examples below.
- Cells which are known to have TGF-B cellular receptors include mouse thymocytes (C3H/HeJ) and the NRK cell line (clone 49F, ATCC CRL 1570).
- terapéuticaally effective amount refers to the amount of antibody that neutralizes the biologic activity of TGF-B, which may be measured by either (1) a pathologic evaluation of the prevention of fibrosis, or (2) an inhibition of the immunosuppressive effects of TGF-B which results in tumor regression.
- anti-TGF-B antibody-producing primary B cells are isolated from a mammal immunized with TGF-B and then immortalized so that a cell line can be established.
- Any appropriate technique of immortalizing the primary B cells can be employed, including, but not limited to, fusion with a myeloma cell, transformation, with oncogenic DNA, or transfection with Epstein-Barr virus.
- Preferred myeloma cells for this purpose are those which do not themselves secrete immunoglobulins, which fuse efficiently, support stable high-level expression of antibody by the selected antibody-producing cells, and are sensitive to selection mediums such as HAT medium.
- myeloma cell lines are murine myeloma lines such as those derived from P3x63-Ag8.653 (653) and Sp2/0-Ag14 (SP2/0) myeloma lines available from the American Type Culture Collection, Rockville, Md., under ATCC CRL Nos. 1580 and 1581, respectively.
- murine myeloma lines such as those derived from P3x63-Ag8.653 (653) and Sp2/0-Ag14 (SP2/0) myeloma lines available from the American Type Culture Collection, Rockville, Md., under ATCC CRL Nos. 1580 and 1581, respectively.
- Immortalized cells such as the murine hybridomas, are screened for production of the desired anti-TGF-B antibodies having the appropriate affinity and/or epitope.
- a particularly useful screen for regularly isolating high affinity antibodies is to screen antibodies using a solid phase radioimmune assay (RIA).
- RIA radioimmune assay
- monoclonal antibodies having binding affinities for TGF-B of at least about 10 7 M ⁇ 1 are selected.
- the present invention regularly permits the isolation of antibodies with binding affinities of at least about 10 7 M ⁇ 1 to about 10 8 M ⁇ 1 .
- the present invention is also directed to anti-TGF-B monoclonal antibodies that neutralize the in vitro inhibitory effects of TGF-B. Screening monoclonal antibodies for this ability can be in addition to the screen for high binding affinity. In general, standard in vitro neutralization assays may be employed in this screen.
- the MAb 1D11.16 is found to neutralize both TGF-B1 and B2 activity. This suggests that a conserved portion of both molecules serves as the MAb binding epitope, and that this epitope is either within or close to the cell receptor binding site of TGF-B.
- Monoclonal antibody 1D11.16 (IgG1) refers to the MAb produced by a clone of the murine hybridoma cell line 1D11.16. Samples of this cell line were deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Md. Cell line 1D11.16 was assigned ATCC HB9849, and is guaranteed to be publicly available for thirty years after the issue date of this patent. Monoclonal antibodies produced by the clones of this cell line may be distinguished using the Western Blot Assay, wherein the antibody MAb 1D11.16 would recognize both TGF-B1 and TGF-B2.
- the antibodies of the present invention may be used to treat acute or chronic fibrosis that is associated with overproduction of TGF-B.
- the body responds to injury or disease by regenerating destroyed tissue.
- the destroyed tissue may be replaced by specialized fibrotic connective tissue. Excess deposition of this fibrotic tissue may result in an impairment of the affected tissue or organ function, and in some instances may be disfiguring to the patient.
- TGF-B in diseases such as interstitial lung fibrosis, liver cirrhosis, and fibrotic skin disorders such as scleroderma and scarring: M. J. Czaja et al, J Cell Biol (1988) (in press); D. G. Hoyt et al, J Pharm Exp Ther (1988) 246:765.
- a therapeutically effective amount of the antibody of this invention may be administered to neutralize the biologic activity of TGF-B, which in turn would result in prevention of unwanted fibrosis.
- TGF-B is produced by different tumor cells (sarcomas and carcinomas). This production may protect the tumor cells from recognition by the host's immune system: M. Wrann et al, EMBO J (1987) 6:1633. In these situations, TGF-B suppresses the proliferation of T and B cells, NK cells, LAK cells, and macrophages that are involved in tumor destruction.
- the MAb of this invention may be administered to block TGF-B's immunosuppressive effects (to permit the generation of an immune response against the tumor), and result in tumor regression.
- the antibody of the invention neutralizes the biological activity of TGF-B by preventing the antigen from binding to its cell surface receptors.
- the intact antibody, antigen binding fragments (e.g., Fab′, F(ab) 2 ), or chimeric antibodies may be useful in these applications.
- administration of the antibodies of the invention would form immune complexes (antigen-antibody complexes) that will increase the rate at which the antigen.
- TGF-B is cleared from systemic circulation or from the tissue site where the antigen is produced.
- fibrotic diseases and tumor cells may be treated by administering a therapeutically effective amount of the antibodies of the invention to affect the inhibition of fibrosis formation or regression of tumor cells.
- the method and frequency of administration, the dose range, and the duration of the antibody therapy will vary with the severity and nature of the condition, and the general health of the patient.
- the antibodies of the invention are administered locally to the affected tissue sites by bolus injection or perfusion.
- the amount of antibody administered may be measured by maintaining the local tissue concentration of TGF-B at about 1-1,000 ug/mL.
- the antibodies may be delivered directly into a tumor mass through a vascular catheter for deep solid tumors, or through a hypodermic needle for superficial or cutaneous tumors.
- the antibodies may be locally administered by a single bolus injection that is repeated over several days, or by continuous administration by perfusion.
- the amount of antibody administered is preferably about 1 ug to 1,000 ug per gram tumor tissue.
- the antibodies of the invention may be administered systemically by intravenous or peritoneal perfusion, or by bolus injection into the subcutaneous tissue or muscle.
- the antibodies may be delivered in vehicles generally known to those skilled in the art, such as saline, balanced salt solutions, isotonic or phosphate buffered saline (pH 7), with or without dextrose.
- the amount of antibody administered may be measured by maintaining the circulating serum concentration between about 1 ug to 5 mg per mL serum.
- Indications where this mode of treatment is particularly useful are systemic diseases such as interstitial lung fibrosis, liver cirrhosis, scleroderma, and metastatic cancer.
- the antibodies of the invention may be administered in combination with other antibodies reactive with TGF-B to reduce the amount of bioavailable factor.
- the antibodies of the present invention may also be used in a number of immunoassays, including assays to purify or quantify TGF-B.
- a monoclonal antibody reactive with TGF-B such as 1D11.16
- This antibody will capture any TGF-B present in a solution of unknown proteins.
- the captured TGF-B is then recognized by a second polyclonal antibody that also recognizes TGF-B.
- the second antibody is preferably of a different subclass or species than the first antibody, to allow the specific recognition of the second antibody by a third antibody (e.g., goat anti-rabbit IgG) that is coupled to peroxidase.
- a third antibody e.g., goat anti-rabbit IgG
- TGF-B binds to the capturing antibody 1D11.16.
- the amount of TGF-B in an unknown solution is quantified by comparison of color development to a standard dilution curve of known amounts of TGF-B. High levels of TGF-B are indicative of the presence of fibrotic disease or tumor mass.
- Bone derived TGF-B1 and B2 were purified from the noncollagenous, guanidine-HCl soluble protein fractions of demineralized bovine metatarsal bone. These factors were purified by a combination of gel filtration, CM-cellulose cation exchange chromatography and C18:reverse phase high pressure liquid chromatography (HPLC) using a previously described method (Seyedin et al, Proc Natl Acad Sci USA (1985) 82:2267). Protein concentrations were determined spectrophotometrically by comparison of absorbance at OD 210 to a solution of protein of known concentration.
- polyethylene glycol 1500 50% polyethylene glycol 1500 (Boehringer-Mannheim Biochemicals, Indianapolis, Ind.) was used as the fusagen.
- Cells were plated at 10 6 cells/well along with resident peritoneal cells at 4 ⁇ 10 3 cells/well in DMEM with high glucose (4.5 g/l) supplemented with 20% FCS (Hyclone Laboratories, Logan, Utah), 2 mM L-glutamine, 2 mM sodium pyruvate, nonessential amino acids, penicillin and streptomycin.
- the ELISA for TGF-B2 was performed according to standard procedures (Ellingsworth et al, J Biol Chem (1986) 261:12362; Engvall and Perlmann, J Immunol (1972) 109:129). Briefly, wells of a 96 well microtiter plate (Immulon, Dynatech Laboratories, Alexandria, Va.) were coated overnight with 0.25 ug/well of TGF-B2 in a 0.01 M carbonate coating buffer (pH 9.6). For ELISAs done with TGF-B2 peptides, 2.5 ug/mL of peptide was coated onto plates overnight. Plates were washed with PBS (pH 7.4) containing 0.05% Tween® 20 (J.
- d Affinity constants were determined by solid phase RIA and nonlinear regression analysis. Four + indicates MAb with highest affinity. Ka determined from three experiments are as follows: 1D11.16, 3.4 ⁇ 10 8 L/mol; 3C7.14, 1.9 ⁇ 10 8 L/mol; 2G1.1.12, 1.6 ⁇ 10 8 L/mol; and 2D7.20, 1.6 ⁇ 10 7 L/mol.
- e Immunoprecipitation was performed by mixing [ 125 I]-labeled TGF-B2 with MAb and followed by addition of anti-Ig-agarose (see FIG. 3). Four + indicates MAb with highest precipitating capability.
- TGF-B2 was electrophoresed in a 15% SDS polyacrylamide gel.
- the protein was then transferred to nitrocellulose in a high pH transfer buffer (25 mM Tris, 192 mM glycine, pH 11; with 20% methanol). After overnight transfer in a Bio-Rad transfer apparatus (170 mA constant current), the blot was blocked with 2.5% non-fat dry milk in PT (PT-BLOTTO).
- FIG. 1 illustrates the Western blot pattern of the binding of the four MAbs to native bovine TGF-B2.
- Lanes 1-6 and 7-12 contain TGF-B2 run under non-reducing and reducing conditions, respectively.
- Lanes 1 and-7 are amido black stained TGF-B2.
- Lanes 2-6 and 8-12 were incubated respectively with the following antibodies: lanes 2 and 8, 2F9.15; lanes 3 and 9, 3C7.14; lanes 4 and 10, 1D11.16; lanes 5 and 11, 2D7.20; and lanes 6 and 12, 2G1.12.
- the monoclonal 3C7.14 is the strongest reactor with TGF-B2 in these blots.
- MAb 2G1.12 reacted very slightly with reduced monomeric TGF-B2; none of the other MAbs are able to bind appreciably to reduced monomeric TGF-B2 (lanes 9-12).
- lanes 2 and 8 Also included in lanes 2 and 8 is the reactivity pattern of an additional MAb that recognizes a protein contaminant present in the biochemically purified TGF-B2 preparations. This pattern is representative for several other MAbs produced that also recognize this identical contaminant (data not presented). On silver staining of PAGE gels, this contaminant was found to represent a small percentage of the immunizing protein.
- FIG. 5 illustrates the binding of MAb 1D11.16 to both TGF-B1 and TGF-B2 under non-reducing conditions.
- Lanes 2-5 and 6-9 contained various amounts of TGF-B2 and TGF-B1, respectively. The amounts were 1 ug/lane (lanes 2 and 9), 0.25 ug/lane (lanes 3 and 8), 0.1 ug/lane (lanes 4 and 7), and 0.025 ug/lane (lanes 5 and 6).
- the lack of reactivity in lane 5 is believed to be an artifact due to loss of the sample during lyophilization prior to running the SDS gel.
- TGF-B The IL-1 and PHA-dependent thymocyte assay for TGF-B described in Ellingsworth et al, Cell Immunol (1988) 114:41 was employed. In these experiments, either 50 or 100 ul of MAb-containing culture supernatant or purified IgG diluted in medium was added to the cultures at the same time as TGF-B1 or B2 The TGF-B concentrations were employed over a range of 10 ⁇ 12 to 10 ⁇ 10 M.
- FIG. 2 shows the ability of affinity purified 1D11.16 to neutralize the anti-proliferative actions of TGF-B.
- This figure demonstrates that the IL-1 and PHA-dependent proliferation of thymocytes is inhibited by TGF-B2 over a concentration range of 10 ⁇ 12 to 10 ⁇ 10 M. Addition of 10 or 100 ug/mL 1D11.16 will effectively neutralize 10 ⁇ 11 M TGF-B2 when both TGF-B 2 and antibody are added at the start of culture.
- 1D11.16 is also found to neutralize the activity of TGF-B1 to a similar extent in this assay. This suggests that a similar epitope on both TGF-B1 and B2 is recognized by the neutralizing antibody and that this epitope may be within or adjacent to the receptor binding site on TGF-B. 1D11.16 is able to neutralize the growth promoting actions of TGF-B1 and B2 in the NRK proliferation assay (Roberts et al, “Purification of type B transforming growth factors from non-neoplastic tissues” in Cell Culture Methods for Molecular and Cell Biology, Barnes et al, eds., Ed. Alan Liss, Inc., New York pp.
- FIG. 3 represents an autoradiogram of TGF-B cross-linked cell receptors from both thymocytes and the NRK cell line. Approximately 1 ⁇ 10 7 thymocytes (lanes 1-4) or 5 ⁇ 10 6 NRK cells (lanes 5-12) were used.
- Lanes 2 and 6 received 20 nM non-labeled TGF-B1 and lane 10 received 20 nM unlabeled TGF-B2 to show the specificity of binding. Lanes 3, 7 and 11 received 1D11.16 Ab.
- the addition of control mouse IgG did not affect TGF-B binding to its receptors Binding of both TGF-B1 and TGF-B2 to the cellular receptors is effectively inhibited by the MAb 1D11.16 (lanes 3, 7, and 11). Only the binding to the 65 Kd receptor is not completely blocked by the antibody.
- TGF-B2 was labeled with [ 125 I]-TGF-B2 by the chloramine T method (Frolik et al, J Biol Chem (1984) 259:10995). 200 ul of MAb-containing culture supernatant or purified IgG in 0.02 M Tris-buffered saline (TBS, pH 8.2) containing 1% sodium deoxy-cholate (Sigma)(DOC) was mixed with 100,000 cpm (specific activity 125 uCi/ul) of [ 125 I]-TGF-B2 for 2 hr at room temperature.
- TBS Tris-buffered saline
- DOC sodium deoxy-cholate
- FIG. 4 shows that the immune complexes are brought down most effectively by the antibody 3C7.14. Counts are expressed as percent specific counts (CPM sample minus nonspecific background/total CPM minus non-specific background). A fair amount of batch to batch variation in the percentage of iodinated TGF-B2 brought down by all the MAbs was observed. This suggests that the chloramine T iodination procedure may convert a considerable amount of the TGF-B into an antigenically altered conformation.
- the MAbs were purified either from culture supernatant or ascites by protein A-Sepharose chromatography (Goding, J Immunol Meth (1976) 42:17) (Pharmacia Fine Chemicals, Uppsala, Sweden).
- the binding of the gamma 1 subclass MAbs, 1D11.16 and 2G1.12, to protein A was enhanced by addition of a commercially prepared binding buffer (Bio-Rad, Richmond, Calif.).
- Antibodies were eluted from the protein A-Sepharose with 0.05 M glycine-HCl plus 0.15 M NaCl buffer (pH 2.3), dialyzed overnight versus PBS and stored at ⁇ 20° C.
- the gamma 1 subclass antibodies purified from supernatants were concentrated and partially purified by ammonium sulfate precipitation (50% saturated) prior to protein A-chromatography.
- This solid phase RIA follows the procedure of Mariani et al, J Immunol Meth (1984) 71:43. Briefly, wells of a 96 well microtiter plate (Microtest III, Becton Dickenson, Oxnard, Calif.) were coated with purified MAbs at 100 ug/well overnight in 0.01 M carbonate coating buffer (pH 9.6). The wells were washed with PT and blocked with PT containing 1% (w/v) gelatin for 60 min. The plates were then washed with PT and incubated with 2 fold dilutions of a solution containing non-labeled TGF-B2 (starting at 20 ug/mL) in PT plus 1% gelatin.
- a hepatotoxin D-galactosamine, causes reproducible mortality, liver fibrosis, and maximal TCF-B gene expression approximately 48 hours after administration.
- a rat model utilizing this hepatotoxin is useful for evaluation of TGF-B antibody therapeutic effects on acute liver fibrosis.
Abstract
Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications utilizing the TGF-B monoclonal antibody are also disclosed.
Description
- The present invention relates to the field of immunology and particularly to monoclonal antibodies specific to transforming growth factor beta (TGF-B) and applications thereof.
- Transforming growth factor beta (TGF-B) is a family of related multifunctional regulators of cell growth which can affect cellular proliferation and differentiation. Two forms of TGF-B, TGF-B1 and TGF-B2, are, in general, multifunctional cytokines that have potent inhibitory effects on the proliferation and effector responses of mitogen-, lymphokine-, and alloantigen-activated lymphocytes (Kearl et al,J Exp Med (1986) 163:1037; Ellingsworth et al, Cell Immunol (1988) 113: in press; Kearl et al, J Immunol (1986) 137:3855; Ranges et al, J Exp Med (1987) 166:991). In addition, TGF-B1 and TGF-B2 affect the proliferation and differentiation of other cells of the immune system including macrophages (Wall et al, Proc Natl Acad Sci USA (1987) 84:5788), pre-B cells (Lee et al, J Exp Med (1987) 166:1290), hematopoietic stem cells (Ohta et al, Nature (1987) 329:539; Ishibashi et al, Blood (1987) 69:1737; Keller et al, J Exp Med (1988) in press; Sing et al, Blood (1988) in press), and NK cells (Rook et al, J Immunol (1986) 136:3916).
- The generation of immunoprecipitating and neutralizing antibodies to native TGF-B has been extremely difficult due to the highly conserved nature of native TGF-B among different species. The human sequence of TGF-B1 is identical to the bovine and porcine sequences and differs from the murine sequence by one amino acid. TGF-B1 is a dimer composed of two identical disulfide-linked chains of 112 amino acid residues.
- TGF-B2 is also a dimeric polypeptide and is disclosed in U.S. Pat. No. 4,774,322, filed Dec. 10, 1987, assigned to Collagen Corporation. Even though there are 14 amino acid differences in the first 36 amino acids residues of the two forms, their biological activities are similar (Cheifetz et al,Cell (1987) 48:409-415; Seyedin et al, J Biol Chem (1987) 262:1946-1949).
- Western blots and immunohistochemical localization studies on TGF-B1 have been performed using a polyclonal rabbit antiserum obtained by immunization with a synthetic peptide corresponding to the NH2-terminal 30 amino acids of TGF-B1 (Ellingsworth et al, J Biol Chem (1986) 261:12362). Polyclonal antisera to human and porcine TGF-B (Keski-Oja et al, Cancer Res (1987) 47:6451-6458) and to porcine TGF-B2 (Rosa et al, Science (1988) 239:783-785) have been shown to neutralize the biological activity of TGF-B1 and TGF-B2, respectively. Monoclonal antibodies specific to TGF-B have not been previously described. The availability of these specific antibodies is important for characterization of the role played by TGF-B in the immune system and other physiological processes.
- Antibodies to TGF-B are needed to investigate the varied biological actions of TGF-B, to study TGF-B biosynthesis, and to determine differences in activity or effect, if any, between the forms of TGF-B. These antibodies would also have therapeutic applications for treating indications where there is an overproduction of TGF-B (e.g., acute liver injury, chronic hepatic fibrosis) and for diagnosing or treating malignancies (e.g., sarcomas and melanomas) and metastatic cancers.
- The present invention provides a monoclonal antibody immunoreactive with TGF-B. A monoclonal antibody is described herein that is specific for TGF-B. This antibody, in preferred embodiments, binds to a neutralizing epitope on TGF-B or binds to an epitope on TGF-B which blocks the binding of TGF-B to its cellular receptors.
- Another aspect of the invention is to provide a stable cell line which secretes a monoclonal antibody specific for TGF-B. In one embodiment of the invention, the cell line secretes a murine monoclonal antibody specific for TGF-B that has TGF-B neutralizing activity.
- Another aspect of the invention is a method for treating acute and chronic disease states that result from an overproduction of TGF-B, by administering a therapeutically effective amount of a monoclonal antibody reactive with TGF-B, or an antigen-binding fragment of a monoclonal antibody reactive with TGF-B.
- Another aspect of the invention is a method for treating tumor cells that produce TGF-B, by administering a therapeutically effective amount of a monoclonal antibody reactive with TGF-B to suppress the immunosuppressive effects of TGF-B.
- Another aspect of the invention is a method for treating metastatic cancers by administering a therapeutically effective amount of a monoclonal antibody reactive with TGF-B to mark tumor cells for destruction by complement or by immune cells dedicated to tumor cell removal Another aspect of the invention is a capture-ELISA (CELISA) for diagnosing disease states such as cancer and connective tissue (fibrotic) disorders comprising: coating a first monoclonal or polyclonal antibody reactive with TGF-B onto a surface, adding a sample containing an unknown amount of TGF-B or a standard concentration of purified TGF-B to the surface, adding polyclonal sera reactive with TGF-B or a monoclonal antibody of the invention to the surface, adding an enzyme-linked tertiary antibody (reactive to said monoclonal or polyclonal antibody), and determining the presence of TGF-B by quantifying the amount of enzymatic label present in a colorimetric reaction.
- Another aspect of the invention is a chimeric monoclonal antibody, having an antigen-binding portion derived from the MAb of the invention, and the remainder derived from human antibodies. Such chimeric antibodies are described by S. L. Morrison,Science (1985) 229:1202.
- Another aspect of the invention is an anti-idio-typic antibody reactive with the MAbs of the invention, which are useful as TGF-B mimics. These mimics are capable of binding to TGF-B receptors, and thus may act as TGF-B agonists or antagonists.
- These and other objects and features of the invention will become more fully apparent from the following detailed description of the invention.
- FIG. 1 is a Western blot of monoclonal antibodies binding to purified TGF-B2. Lanes 1-6 and 7-12 contain TGF-B2 run under non-reducing and reducing conditions, respectively.
- FIG. 2 illustrates the neutralization of TGF-B2 activity by the 1D11.16 MAb.
- FIG. 3 represents an autoradiogram showing inhibition of affinity cross-linked cell receptors from both thymocytes and the NRK cell line by MAbs.
- FIG. 4 illustrates the immunoprecipitation of [125I]-labeled TGF-B2.
- FIG. 5 is a Western blot of monoclonal antibody 1D11.16 binding to purified TGF-B1 and TGF-B2. Lanes 2-5 and 6-9 contain various amounts of TGF-B2 and TGF-B1, respectively, run under non-reducing conditions.
- The present invention is directed broadly to the production of TGF-B monoclonal antibodies, neutralizing TGF-B antibodies and TGF-B antibodies that block the binding of TGF-B to cellular receptors. The present invention is also directed to the use of such antibodies in diagnostic assays to determine elevated levels of TGF-B that are associated with certain disease states, and in therapeutic applications to prevent the overproduction of TGF-B or to suppress the immunosuppressive effects of TGF-B in tumor cells.
- A. Definitions
- As used herein the terms “monoclonal antibody” and “MAb” refer to an immunoglobulin composition having a substantially homogenous population of antibodies, each of which binds to the same antigenic determinant Unless otherwise indicated, the term is not intended to be limited to antibodies of any particular mammalian species or isotype, or to antibodies prepared in any given manner. The term is intended to include whole antibody molecules as well as antigen-binding fragments (e.g., Fab′, F(ab′)2).
- “Cell line” refers to various embodiments including but not limited to individual cells, harvested cells, and cultures containing cells so long as they are derived from cells of the cell line referred to.
- As used herein with respect to characterizing the claimed hybrid cell lines, the terms “permanent” and “stable” mean that the lines remain viable over a period of time, typically at least about six months, and maintain the ability to produce the specified monoclonal antibody through at least about 50 passages.
- “TGF-B” refers in general to the family of transforming growth factors (beta-chain) which participate in the control of cell proliferation and differentiation. As used herein the term refers to both TGF-B1 and TGF-B2 proteins. Other known TGF-B-like proteins are the “inhibins” (Mason et al,Nature (1985) 318:659-663), their beta-chain dimers, “activins” (Ling et al, Nature (1986) 321:779-782; Vale et al, Nature (1986) 321:776-779), Mullerian inhibiting substance (Cate et al, Cell (1986) 45:685-698) and a predicted protein product of the decapentaplegic gene complex of Drosophila (Padgett et al, Nature (1987) 325:81-84) as shown by complementary DNA sequence analysis.
- An antibody that “is reactive with” or “specific to” TGF-B is an antibody that binds an epitope present on TGF-B.
- An antibody that “neutralizes in vitro biological activity of TGF-B” when bound to its epitope on TGF-B is defined by testing the antibody-bound TGF-B in an in vitro assay such as the IL-1 and PHA-dependent thymocyte proliferation assay, the NRK proliferation assay or an assay using the ROS 17.2.8 osteosarcoma cell line, all of which are described in the following examples.
- An antibody that “blocks binding to cellular receptors” of TGF-B is an antibody that blocks the binding of TGF-B to TGF-B cellular receptors in a standard receptor binding assay, such as the one described in the examples below. Cells which are known to have TGF-B cellular receptors include mouse thymocytes (C3H/HeJ) and the NRK cell line (clone 49F, ATCC CRL 1570).
- The term “binding affinity” or Ka” of an antibody to its epitope, as used herein, refers to a binding affinity that may be calculated according to standard methods by the formula Ka=8/3 (It-Tt) where It is the total molar concentration of inhibitor uptake at 50% tracer and Tt is the total molar concentration of tracer. See Muller, J Immunol Meth (1980) 34:345-352. Binding affinity may also be calculated using the formula B/T n·NAb ·W·[(V−Vm)K+Q·W]. See Antoni and Mariani, J Immunol Meth (1985) 83:61.
- The term “therapeutically effective amount” as used herein refers to the amount of antibody that neutralizes the biologic activity of TGF-B, which may be measured by either (1) a pathologic evaluation of the prevention of fibrosis, or (2) an inhibition of the immunosuppressive effects of TGF-B which results in tumor regression.
- The general procedures of producing monoclonal antibodies, including the cell lines which produce such compositions, are well known in the art. See, e.g., Gerhard et al,Proc Natl Acad Sci USA (1978) 75:1510; Monoclonal Antibodies (R. Kennett, T. McKearn, & K. Bechtol eds. 1980); Monoclonal Antibodies and T-Cell Hybridomas (G. Hammerling, U. Hammerling, & J. Kearney eds. 1981); Kozbor et al, Proc Natl Acad Sci USA (1982) 79:6651; Jonak et al, Hybridoma (1983) 2:124; Monoclonal Antibodies and Functional Cell Lines (R. Kennett, K Bechtol, & T. McKearn eds. 1983); Kozbor et al, Immunology Today (1983) 4:72-79; Shulman et al, Nature (1982) 276:269-270; Oi et al, in Selected Methods in Cellular Immunology, pp. 351-371 (B. Mishell & S. Schiigi eds. 1980); and Foung et al, Proc Natl Acad Sci USA (1983) 79:7484-7488.
- In a preferred embodiment, anti-TGF-B antibody-producing primary B cells are isolated from a mammal immunized with TGF-B and then immortalized so that a cell line can be established. Any appropriate technique of immortalizing the primary B cells can be employed, including, but not limited to, fusion with a myeloma cell, transformation, with oncogenic DNA, or transfection with Epstein-Barr virus. Preferred myeloma cells for this purpose are those which do not themselves secrete immunoglobulins, which fuse efficiently, support stable high-level expression of antibody by the selected antibody-producing cells, and are sensitive to selection mediums such as HAT medium. Among these, presently preferred myeloma cell lines are murine myeloma lines such as those derived from P3x63-Ag8.653 (653) and Sp2/0-Ag14 (SP2/0) myeloma lines available from the American Type Culture Collection, Rockville, Md., under ATCC CRL Nos. 1580 and 1581, respectively.
- Immortalized cells, such as the murine hybridomas, are screened for production of the desired anti-TGF-B antibodies having the appropriate affinity and/or epitope. A particularly useful screen for regularly isolating high affinity antibodies is to screen antibodies using a solid phase radioimmune assay (RIA). Generally, monoclonal antibodies having binding affinities for TGF-B of at least about 107 M−1 are selected. The present invention regularly permits the isolation of antibodies with binding affinities of at least about 107 M−1 to about 108 M−1.
- The present invention is also directed to anti-TGF-B monoclonal antibodies that neutralize the in vitro inhibitory effects of TGF-B. Screening monoclonal antibodies for this ability can be in addition to the screen for high binding affinity. In general, standard in vitro neutralization assays may be employed in this screen. In a preferred embodiment of the present invention, the MAb 1D11.16 is found to neutralize both TGF-B1 and B2 activity. This suggests that a conserved portion of both molecules serves as the MAb binding epitope, and that this epitope is either within or close to the cell receptor binding site of TGF-B. Work by Flanders et al,Biochem (1988) 27:739-746 with polyclonal antisera raised against synthetic peptides corresponding to different regions of TGF-B1 implicated the C-terminal portion of TGF-B1 in receptor binding. Comparison of the C-terminal sequences of TGF-B1 and B2 reveals only 7 differences in the final 30 amino acid residues of the molecules. Since the most highly conserved portion of the molecules is actually between
residues 20 and 44, it appears possible that this region is a target for the cell receptor binding site on TGF-B. - Several preferred murine monoclonal antibodies have been produced according to the present invention. Monoclonal antibody 1D11.16 (IgG1) refers to the MAb produced by a clone of the murine hybridoma cell line 1D11.16. Samples of this cell line were deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Md. Cell line 1D11.16 was assigned ATCC HB9849, and is guaranteed to be publicly available for thirty years after the issue date of this patent. Monoclonal antibodies produced by the clones of this cell line may be distinguished using the Western Blot Assay, wherein the antibody MAb 1D11.16 would recognize both TGF-B1 and TGF-B2. The antibodies of the present invention may be used to treat acute or chronic fibrosis that is associated with overproduction of TGF-B. The body responds to injury or disease by regenerating destroyed tissue. When the injury or disease is prolonged or extensive, the destroyed tissue may be replaced by specialized fibrotic connective tissue. Excess deposition of this fibrotic tissue may result in an impairment of the affected tissue or organ function, and in some instances may be disfiguring to the patient. It is currently believed that there is an overproduction of TGF-B in diseases such as interstitial lung fibrosis, liver cirrhosis, and fibrotic skin disorders such as scleroderma and scarring: M. J. Czaja et al,J Cell Biol (1988) (in press); D. G. Hoyt et al, J Pharm Exp Ther (1988) 246:765. A therapeutically effective amount of the antibody of this invention may be administered to neutralize the biologic activity of TGF-B, which in turn would result in prevention of unwanted fibrosis.
- It is also generally known that TGF-B is produced by different tumor cells (sarcomas and carcinomas). This production may protect the tumor cells from recognition by the host's immune system: M. Wrann et al,EMBO J (1987) 6:1633. In these situations, TGF-B suppresses the proliferation of T and B cells, NK cells, LAK cells, and macrophages that are involved in tumor destruction. The MAb of this invention may be administered to block TGF-B's immunosuppressive effects (to permit the generation of an immune response against the tumor), and result in tumor regression.
- The antibody of the invention neutralizes the biological activity of TGF-B by preventing the antigen from binding to its cell surface receptors. The intact antibody, antigen binding fragments (e.g., Fab′, F(ab)2), or chimeric antibodies may be useful in these applications. In addition, administration of the antibodies of the invention would form immune complexes (antigen-antibody complexes) that will increase the rate at which the antigen. TGF-B, is cleared from systemic circulation or from the tissue site where the antigen is produced.
- These types of fibrotic diseases and tumor cells may be treated by administering a therapeutically effective amount of the antibodies of the invention to affect the inhibition of fibrosis formation or regression of tumor cells. The method and frequency of administration, the dose range, and the duration of the antibody therapy will vary with the severity and nature of the condition, and the general health of the patient.
- In a preferred embodiment, the antibodies of the invention are administered locally to the affected tissue sites by bolus injection or perfusion. The amount of antibody administered may be measured by maintaining the local tissue concentration of TGF-B at about 1-1,000 ug/mL.
- Indications where this mode of treatment is particularly useful are for the control of excessive scar tissue formation, due to surgery or trauma, or prevention of the formation of connective tissue adhesions. For treatment of tumor cells by local administration, the antibodies may be delivered directly into a tumor mass through a vascular catheter for deep solid tumors, or through a hypodermic needle for superficial or cutaneous tumors. The antibodies may be locally administered by a single bolus injection that is repeated over several days, or by continuous administration by perfusion. The amount of antibody administered is preferably about 1 ug to 1,000 ug per gram tumor tissue.
- In another preferred embodiment, the antibodies of the invention may be administered systemically by intravenous or peritoneal perfusion, or by bolus injection into the subcutaneous tissue or muscle. The antibodies may be delivered in vehicles generally known to those skilled in the art, such as saline, balanced salt solutions, isotonic or phosphate buffered saline (pH 7), with or without dextrose. The amount of antibody administered may be measured by maintaining the circulating serum concentration between about 1 ug to 5 mg per mL serum.
- Indications where this mode of treatment is particularly useful are systemic diseases such as interstitial lung fibrosis, liver cirrhosis, scleroderma, and metastatic cancer.
- For both local and systemic treatment, the antibodies of the invention may be administered in combination with other antibodies reactive with TGF-B to reduce the amount of bioavailable factor.
- The antibodies of the present invention may also be used in a number of immunoassays, including assays to purify or quantify TGF-B. For example, in one embodiment, a monoclonal antibody reactive with TGF-B, such as 1D11.16, is coated onto microtiter wells. This antibody will capture any TGF-B present in a solution of unknown proteins. The captured TGF-B is then recognized by a second polyclonal antibody that also recognizes TGF-B. The second antibody is preferably of a different subclass or species than the first antibody, to allow the specific recognition of the second antibody by a third antibody (e.g., goat anti-rabbit IgG) that is coupled to peroxidase. Thus, in this assay, color development only occurs when TGF-B binds to the capturing antibody 1D11.16. The amount of TGF-B in an unknown solution is quantified by comparison of color development to a standard dilution curve of known amounts of TGF-B. High levels of TGF-B are indicative of the presence of fibrotic disease or tumor mass.
- The following examples are presented for illustrative purposes only and are not to limit the scope of the present invention. Variations in the source, type, and method of producing antibodies will be apparent to those of ordinary skill in the art, and may be employed without departing from the scope of the present invention.
- Bone derived TGF-B1 and B2 were purified from the noncollagenous, guanidine-HCl soluble protein fractions of demineralized bovine metatarsal bone. These factors were purified by a combination of gel filtration, CM-cellulose cation exchange chromatography and C18:reverse phase high pressure liquid chromatography (HPLC) using a previously described method (Seyedin et al,Proc Natl Acad Sci USA (1985) 82:2267). Protein concentrations were determined spectrophotometrically by comparison of absorbance at OD210 to a solution of protein of known concentration.
- A group of female Balb/c mice was injected intraperitoneally (IP) with 10 ug of native bovine TGF-B2 with complete Freund's adjuvant (Sigma Chemical Co., St. Louis, Mo.). At 3 week intervals, the animals were boosted with 10 ug of TGF-B2 in incomplete Freund's adjuvant (Sigma). Following the second boost, the mice were bled and serum antibody titers against TGF-B2 checked by ELISA. The animal with the highest titer (recip. dil.=5120) was given a final intravenous (IV) injection of TGF-B2 three weeks after the last IP boost and sacrificed for use in the fusion process. For all injections, the TGF-B2 was lyophilized with carrier mouse serum albumin (10 ug albumin per ug TGF-B2) prior to solubilization and injection.
- Fusion to the SP2/0 myeloma (GM3659 B, NIGMS Human Genetic Mutant Cell Repository, Camden, N.J.) was performed 4 days after the IV challenge. The fusion was performed essentially according to the protocol of Oi and Herzenberg, “Immunoglobulin-producing hybrid cell lines” in Selected Methods in Cellular Immunology, Mishell and Shiigi, eds., W. H. Freeman and Co., San Francisco, pp. 357-362, (1980). Spleen cells were mixed with SP2/0 at a ratio of 5:1 (2.2×108 splenocytes: 4.4×107 SP2/0 cells). 50% polyethylene glycol 1500 (Boehringer-Mannheim Biochemicals, Indianapolis, Ind.) was used as the fusagen. Cells were plated at 106 cells/well along with resident peritoneal cells at 4×103 cells/well in DMEM with high glucose (4.5 g/l) supplemented with 20% FCS (Hyclone Laboratories, Logan, Utah), 2 mM L-glutamine, 2 mM sodium pyruvate, nonessential amino acids, penicillin and streptomycin. In this procedure, aminopterin was replaced by azaserine (Sigma) according to the procedure by Larrick et al, Proc Natl Acad Sci USA (1983) 80:6376, and added along with thymidine and hypoxanthine on
day 1 after the fusion. In this fusion, virtually every well contained selection-resistant colonies that were screened for anti-TGF-B2 MAb production by ELISA. All wells positive for TGF-B2, MAb were cloned by limiting dilution. - The ELISA for TGF-B2 was performed according to standard procedures (Ellingsworth et al,J Biol Chem (1986) 261:12362; Engvall and Perlmann, J Immunol (1972) 109:129). Briefly, wells of a 96 well microtiter plate (Immulon, Dynatech Laboratories, Alexandria, Va.) were coated overnight with 0.25 ug/well of TGF-B2 in a 0.01 M carbonate coating buffer (pH 9.6). For ELISAs done with TGF-B2 peptides, 2.5 ug/mL of peptide was coated onto plates overnight. Plates were washed with PBS (pH 7.4) containing 0.05% Tween® 20 (J. T. Baker, Phillipsburg, N.J.) (PT buffer). Plates were blocked with PT containing 1% (w/v) gelatin for 60 min at room temperature. After addition of culture supernatants or purified antibody for 60 min, plates were washed and incubated with 2nd step antibody (peroxidase-conjugated goat anti-mouse IgG, Southern Biotechnology, Birmingham, Ala.). After an additional 60 min, plates were washed and incubated with a one component peroxidase substrate solution (ABTS) (Kirkegaard and Perry, Gaithersburg, Md.). Plates were read with a titretek Multiscan MCC ELISA reader (Flow Laboratories, McLean, Va.). Identification of MAb subclasses was accomplished by ELISA as taught above, except that subclass specific secondary Abs were employed (rat anti-mouse MAb-peroxidase conjugates, Zymed, South San Francisco, Calif.).
- Table I below summarizes some of the characteristics of each of these MAbs. Of particular interest are the relative affinity measurements of the binding of the MAb to TGF-B2 as assessed by a solid phase competitive RIA. The MAb 1D11.16 exhibits the highest affinity for TGF-B2. However, the affinities of all the MAb are relatively similar. Also of interest is the fact that only one of the MAbs, 1D11.16, cross-reacts with TGF-B1 by ELISA.
TABLE I Properties of Anti-TGF-B Monoclonal Antibodies Neutral- X-reacts izing Relative MAb Subclass with B1 Activity Affinity Imppt. 3C7.14 2B − − +++ ++++ 1D11.16 1 + + ++++ ++ 2G1.1.12 1 − − ++ +++ 2D7.20 2A − − + + - a Subclasses were determined by ELISA.
- b Cross-reactions were determined by ELISA with TGF-B1 coated plates.
- c Neutralization was determined in the Il-1, PHA-dependent thymocyte assay (see FIG. 5).
- d Affinity constants were determined by solid phase RIA and nonlinear regression analysis. Four + indicates MAb with highest affinity. Ka determined from three experiments are as follows: 1D11.16, 3.4×108 L/mol; 3C7.14, 1.9×108 L/mol; 2G1.1.12, 1.6×108 L/mol; and 2D7.20, 1.6×107 L/mol.
- e Immunoprecipitation was performed by mixing [125I]-labeled TGF-B2 with MAb and followed by addition of anti-Ig-agarose (see FIG. 3). Four + indicates MAb with highest precipitating capability.
- Mapping of the epitopes recognized by the MAbs was attempted by running ELISAs with synthetic peptides corresponding to portions of TGF-B2 as coating antigens. Three peptides were tested: 1-29, 47-76, 79-108. None of the MAbs were found to bind appreciably to the synthetic peptides even though a 30-fold molar excess of peptide was coated relative to the amount of TGF-B2 normally coated onto plates. A possible explanation for this result may be provided by the Western analysis (see below). In the Westerns, only the MAb 2G1.1.12 weakly recognized the reduced monomeric form of the molecule.
- This protocol follows standard procedures (Ellingsworth et al, (1986) supra; Towbin et al,Proc Natl Acad Sci USA (1979) 76:4350. TGF-B2 was electrophoresed in a 15% SDS polyacrylamide gel. The protein was then transferred to nitrocellulose in a high pH transfer buffer (25 mM Tris, 192 mM glycine,
pH 11; with 20% methanol). After overnight transfer in a Bio-Rad transfer apparatus (170 mA constant current), the blot was blocked with 2.5% non-fat dry milk in PT (PT-BLOTTO). The nitro-cellulose strips were incubated with MAb-containing supernatants or purified IgG in PT-BLOTTO for 60 min. After washing, the strips were incubated with the previously-described 2nd step antibody (peroxidase-conjugated goat anti-mouse IgG) for an additional 60 min The presence of antibody was visualized by addition of the peroxidase substrate: 0.06% (w/v) 4-chloro-1-napthol (Sigma) and 0.01% hydrogen peroxide in 0.05 M Tris-buffered saline (pH 7.4). The reaction procedure was halted by extensive washing of the blot in deionized H2O. - FIG. 1 illustrates the Western blot pattern of the binding of the four MAbs to native bovine TGF-B2. Lanes 1-6 and 7-12 contain TGF-B2 run under non-reducing and reducing conditions, respectively.
Lanes 1 and-7 are amido black stained TGF-B2. Lanes 2-6 and 8-12 were incubated respectively with the following antibodies:lanes lanes lanes lanes lanes lanes - FIG. 5 illustrates the binding of MAb 1D11.16 to both TGF-B1 and TGF-B2 under non-reducing conditions. Lanes 2-5 and 6-9 contained various amounts of TGF-B2 and TGF-B1, respectively. The amounts were 1 ug/lane (
lanes 2 and 9), 0.25 ug/lane (lanes 3 and 8), 0.1 ug/lane (lanes 4 and 7), and 0.025 ug/lane (lanes 5 and 6). The lack of reactivity inlane 5 is believed to be an artifact due to loss of the sample during lyophilization prior to running the SDS gel. - The IL-1 and PHA-dependent thymocyte assay for TGF-B described in Ellingsworth et al,Cell Immunol (1988) 114:41 was employed. In these experiments, either 50 or 100 ul of MAb-containing culture supernatant or purified IgG diluted in medium was added to the cultures at the same time as TGF-B1 or B2 The TGF-B concentrations were employed over a range of 10−12 to 10−10 M.
- Preliminary experiments showed that only one of the four MAbs, 1D11.16, was able to neutralize the inhibitory effects of TGF-B. FIG. 2 shows the ability of affinity purified 1D11.16 to neutralize the anti-proliferative actions of TGF-B. This figure demonstrates that the IL-1 and PHA-dependent proliferation of thymocytes is inhibited by TGF-B2 over a concentration range of 10−12 to 10−10 M. Addition of 10 or 100 ug/mL 1D11.16 will effectively neutralize 10 −11M TGF-B2 when both TGF-
B 2 and antibody are added at the start of culture. 1D11.16 is also found to neutralize the activity of TGF-B1 to a similar extent in this assay. This suggests that a similar epitope on both TGF-B1 and B2 is recognized by the neutralizing antibody and that this epitope may be within or adjacent to the receptor binding site on TGF-B. 1D11.16 is able to neutralize the growth promoting actions of TGF-B1 and B2 in the NRK proliferation assay (Roberts et al, “Purification of type B transforming growth factors from non-neoplastic tissues” in Cell Culture Methods for Molecular and Cell Biology, Barnes et al, eds., Ed. Alan Liss, Inc., New York pp. 181-194, (1984)) and to neutralize TGF-B induced alkaline phosphatase production in an assay using the ROS 17.2.8 osteosarcoma cell line (obtained from Dr. Greg Mundy, U. Texas Health Science Center, San Antonio, Tex.). These results suggest that a single receptor binding domain is present in TGF-B1 and B2 and that this binding domain appears to be responsible for the pleiotropic actions attributed to TGF-B1 and B2. - The cross-linking of [125I]-labeled TGF-B1 and B2 to its cellular receptors employs the methods described in Ellingsworth et al (1986) supra and Segarini et al, J Biol Chem (1987) 262:14655. In the current experiments, either 1D11.16 antibody (30 ug/mL) or a non-TGF-B-reactive mouse MAb at an equivalent concentration was pre-mixed with [125]-labeled TGF-B1 or B2 (50 pM final concentration) for 60 min prior to addition to the cells. The cells employed in the assay were freshly isolated mouse thymocytes (C3H/HeJ) and the NRK cell line (clone 49F, CRL 1570).
- The ability of the MAb 1D11.16 to block the cross-linking of [125I]-labeled TGF-B by addition of disuccinimidyl suberate (DSS) to its cell surface receptor complex was assessed. The receptor complex consists of three major species that have approximate molecular weights of 65 kilodaltons (Kd), 85-95 Kd, and 200-280 Kd. FIG. 3 represents an autoradiogram of TGF-B cross-linked cell receptors from both thymocytes and the NRK cell line. Approximately 1×107 thymocytes (lanes 1-4) or 5×106 NRK cells (lanes 5-12) were used.
Lanes lane 10 received 20 nM unlabeled TGF-B2 to show the specificity of binding.Lanes lanes lanes - The ability of the different MAbs to precipitate iodinated TGF-B2 was assessed. TGF-B2 was labeled with [125I]-TGF-B2 by the chloramine T method (Frolik et al, J Biol Chem (1984) 259:10995). 200 ul of MAb-containing culture supernatant or purified IgG in 0.02 M Tris-buffered saline (TBS, pH 8.2) containing 1% sodium deoxy-cholate (Sigma)(DOC) was mixed with 100,000 cpm (
specific activity 125 uCi/ul) of [125I]-TGF-B2 for 2 hr at room temperature. To this solution, 50 ul of a 50% suspension of goat anti-mouse IgG-agarose (Zymed) was added in TBS-DOC buffer for an additional 45 min with rocking. The agarose beads were washed 3× by centrifugation in TBS-DOC. The pelleted agarose was counted in a gamma counter (Beckman Gamma 5500, Palo Alto, Calif.). Addition of 1% DOC was necessary to limit nonspecific binding of the TGF-B to anti-Ig-agarose. - FIG. 4 shows that the immune complexes are brought down most effectively by the antibody 3C7.14. Counts are expressed as percent specific counts (CPM sample minus nonspecific background/total CPM minus non-specific background). A fair amount of batch to batch variation in the percentage of iodinated TGF-B2 brought down by all the MAbs was observed. This suggests that the chloramine T iodination procedure may convert a considerable amount of the TGF-B into an antigenically altered conformation.
- The MAbs were purified either from culture supernatant or ascites by protein A-Sepharose chromatography (Goding,J Immunol Meth (1976) 42:17) (Pharmacia Fine Chemicals, Uppsala, Sweden). The binding of the
gamma 1 subclass MAbs, 1D11.16 and 2G1.12, to protein A was enhanced by addition of a commercially prepared binding buffer (Bio-Rad, Richmond, Calif.). Antibodies were eluted from the protein A-Sepharose with 0.05 M glycine-HCl plus 0.15 M NaCl buffer (pH 2.3), dialyzed overnight versus PBS and stored at −20° C. Thegamma 1 subclass antibodies purified from supernatants were concentrated and partially purified by ammonium sulfate precipitation (50% saturated) prior to protein A-chromatography. - This solid phase RIA follows the procedure of Mariani et al,J Immunol Meth (1984) 71:43. Briefly, wells of a 96 well microtiter plate (Microtest III, Becton Dickenson, Oxnard, Calif.) were coated with purified MAbs at 100 ug/well overnight in 0.01 M carbonate coating buffer (pH 9.6). The wells were washed with PT and blocked with PT containing 1% (w/v) gelatin for 60 min. The plates were then washed with PT and incubated with 2 fold dilutions of a solution containing non-labeled TGF-B2 (starting at 20 ug/mL) in PT plus 1% gelatin. To each well was added a constant amount of [125I]-TGF-B2 (100,000 cpm; specific activity 100-150 uCi/ug). After 2-5 hr at room temperature, the plate was thoroughly washed. Individual wells were cut from the plate and counted in a gamma counter. Calculation of affinity constants was performed using a nonlinear regression analysis program (Antoni and Mariani, J Immunol Meth (1985) 83:61). The affinity constants, provided in Table 1, ranged from 1.6×107 L/mol to 3.4×108 L/mol.
- A hepatotoxin, D-galactosamine, causes reproducible mortality, liver fibrosis, and maximal TCF-B gene expression approximately 48 hours after administration. A rat model utilizing this hepatotoxin is useful for evaluation of TGF-B antibody therapeutic effects on acute liver fibrosis.
- Twenty Sprague-Dawley rats were administered 1.6 g/Kg D-galactosamine intraperitoneally. Ten of the rats also received 2 mg/Kg TGF-B antibody (1D11.16) 2 hours prior to hepatotoxin administration, and at 24, 48, and 72 hours post administration. Two rats from each test group were sacrificed at 48 hours to evaluate antibody efficacy at peak TGF-B gene expression.
- Histological examination revealed that anti-TGF-B treated animals exhibited reduced liver pathology. Northern blot evaluation of tissues from specimens treated with TGF-B antibody showed significantly decreased levels of collagen mRNA, and almost normal levels of serum albumin, in contrast to non-treated controls.
- Modifications of the above-described modes for carrying out the invention that are obvious to those of skill in the fields of hybridoma technology, immunology, and related fields, are intended to be within the scope of the following claims.
Claims (15)
1. A monoclonal antibody reactive with transforming growth factor-beta.
2. The monoclonal antibody of claim 1 which binds an epitope on TGF-B wherein the binding affinity of said monoclonal antibody to said epitope at least about 107 M−1.
3. The monoclonal antibody of claim 1 which is a murine antibody.
4. The monoclonal antibody of claim 1 which binds an epitope on TGF-B and neutralizes the inhibitory effects of TGF-B.
5. The monoclonal antibody of claim 4 which is obtained from hybridoma 1D11.16.
6. The monoclonal antibody of claim 1 binding an epitope on TGF-B wherein the binding of the antibody to said epitope blocks the binding of said TGF-B to TGF-B cellular receptors.
7. The monoclonal antibody of claim 1 wherein said antibody is reactive with native bovine TGF-B1 or TGF-B2.
8. A stable, permanent cell line which produces the antibody of claim 1 .
9. The cell line of claim 8 which has the characteristics of the hybridoma cell line HB 9849.
10. The monoclonal antibody 1D11.16.
11. A method for preventing acute or chronic fibrosis, comprising administering a therapeutically effective amount of a monoclonal antibody reactive with TGF-B.
12. The method of claim 12 wherein the monoclonal antibody reactive with TGF-B binds an epitope on TGF-B, thereby blocking the binding of TGF-B to TGF-B cellular receptors.
13. A method for neutralizing the inhibitory effects of TGF-B, which method comprises administering a therapeutically effective amount of a monoclonal antibody reactive with TGF-B.
14. The method of claim 13 wherein the monoclonal antibody is obtained from hybridoma 1D11.16.
15. A method for inducing tumor regression in a mammal having tumor cells which produce TGF-B, which method comprises:
administering an amount of a monoclonal antibody reactive with TGF-B sufficient to reduce the immunosuppressive effects of TGF-B produced by said tumor cells.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/173,074 US20020176858A1 (en) | 1988-12-22 | 2002-06-17 | Monoclonal antibodies to TGF-BETA |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28843288A | 1988-12-22 | 1988-12-22 | |
US07/759,109 US5571714A (en) | 1988-12-22 | 1991-09-06 | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US08/434,976 US5772998A (en) | 1988-12-22 | 1995-05-04 | Monoclonal antibodies to transforming growth factor-beta and methods of use |
US09/097,843 US6090383A (en) | 1988-12-22 | 1998-06-15 | Monoclonal antibodies to transforming growth factor-β and methods of use |
US09/531,383 US6419928B1 (en) | 1988-12-22 | 2000-03-21 | Monoclonal antibodies to transforming growth factor-beta and methods of use |
US10/173,074 US20020176858A1 (en) | 1988-12-22 | 2002-06-17 | Monoclonal antibodies to TGF-BETA |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/531,383 Continuation US6419928B1 (en) | 1988-12-22 | 2000-03-21 | Monoclonal antibodies to transforming growth factor-beta and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020176858A1 true US20020176858A1 (en) | 2002-11-28 |
Family
ID=23107075
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/759,109 Expired - Lifetime US5571714A (en) | 1988-12-22 | 1991-09-06 | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US08/434,976 Expired - Lifetime US5772998A (en) | 1988-12-22 | 1995-05-04 | Monoclonal antibodies to transforming growth factor-beta and methods of use |
US08/434,977 Expired - Lifetime US5783185A (en) | 1988-12-22 | 1995-05-04 | Monoclonal antibodies to transforming growth factor-beta and methods of use |
US09/097,843 Expired - Lifetime US6090383A (en) | 1988-12-22 | 1998-06-15 | Monoclonal antibodies to transforming growth factor-β and methods of use |
US09/531,383 Expired - Fee Related US6419928B1 (en) | 1988-12-22 | 2000-03-21 | Monoclonal antibodies to transforming growth factor-beta and methods of use |
US10/173,074 Abandoned US20020176858A1 (en) | 1988-12-22 | 2002-06-17 | Monoclonal antibodies to TGF-BETA |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/759,109 Expired - Lifetime US5571714A (en) | 1988-12-22 | 1991-09-06 | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US08/434,976 Expired - Lifetime US5772998A (en) | 1988-12-22 | 1995-05-04 | Monoclonal antibodies to transforming growth factor-beta and methods of use |
US08/434,977 Expired - Lifetime US5783185A (en) | 1988-12-22 | 1995-05-04 | Monoclonal antibodies to transforming growth factor-beta and methods of use |
US09/097,843 Expired - Lifetime US6090383A (en) | 1988-12-22 | 1998-06-15 | Monoclonal antibodies to transforming growth factor-β and methods of use |
US09/531,383 Expired - Fee Related US6419928B1 (en) | 1988-12-22 | 2000-03-21 | Monoclonal antibodies to transforming growth factor-beta and methods of use |
Country Status (1)
Country | Link |
---|---|
US (6) | US5571714A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005097832A3 (en) * | 2004-03-31 | 2005-12-01 | Genentech Inc | Humanized anti-tgf-beta antibodies |
WO2019077037A1 (en) | 2017-10-18 | 2019-04-25 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Methods and compounds for improved immune cell therapy |
WO2021202320A1 (en) * | 2020-03-30 | 2021-10-07 | Yale University | Methods for treating inflammatory and fibrotic diseases and disorders |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5583103A (en) | 1988-06-28 | 1996-12-10 | La Jolla Cancer Research Foundation | Inhibition of transforming growth factor beta activity |
US6509314B1 (en) * | 1988-06-28 | 2003-01-21 | The Burnham Institute | Methods of preventing or reducing scarring with decorin or biglycan |
US5654270A (en) * | 1988-06-28 | 1997-08-05 | La Jolla Cancer Research Foundation | Use of fibromodulin to prevent or reduce dermal scarring |
US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US7214375B1 (en) | 1989-09-29 | 2007-05-08 | La Jolla Cancer Research Foundation | Methods of decreasing the accumulation of extracellular matrix associated with glomerulonephritis with anti-TGF-β-specific antibodies |
US20040028682A1 (en) * | 1989-09-29 | 2004-02-12 | Border Wayne A. | Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US6395494B1 (en) * | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6197789B1 (en) | 1995-06-07 | 2001-03-06 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
GB9601081D0 (en) * | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
US7368111B2 (en) * | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
AU6959898A (en) | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
US7723473B2 (en) * | 1997-06-19 | 2010-05-25 | St. Louis University | Peptide antagonists of TGF-beta family members and therapeutic uses thereof |
WO2000001410A1 (en) * | 1998-07-06 | 2000-01-13 | Beth Israel Deaconess Medical Center | Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis |
ATE338120T2 (en) | 1998-11-27 | 2006-09-15 | Ucb Sa | COMPOSITIONS AND METHODS FOR INCREASE BONE MINERALIZATION |
CA2358400C (en) | 1999-01-05 | 2012-05-15 | Nancy A. Noble | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
US7763580B2 (en) | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
US7112409B2 (en) * | 1999-01-29 | 2006-09-26 | Center For Molecular Medicine And Immunology | Method of determining cytokine dosage for myelosuppressive state |
US6649352B1 (en) * | 1999-01-29 | 2003-11-18 | Center For Molecular Medicine And Immunology | Method of evaluating myelosuppressive state |
US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
WO2001051928A1 (en) * | 2000-01-12 | 2001-07-19 | Ventana Medical Systems, Inc. | Method for quantitating a protein by image analysis |
US20040197333A1 (en) * | 2000-02-10 | 2004-10-07 | Cornell Research Foundation, Inc. | Use of TGF-beta antagonists to inhibit tumor cell formation or progression |
WO2001066140A1 (en) | 2000-03-09 | 2001-09-13 | Genzyme Corporation | Use of tgf-beta antagonists to treat or to prevent loss of renal function |
EP1133988A1 (en) * | 2000-03-11 | 2001-09-19 | Biognostik Gesellschaft für biomolekulare Diagnostik mbH | Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
US6756215B1 (en) | 2000-10-20 | 2004-06-29 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Functionalized TGF-β fusion proteins |
US20030125251A1 (en) * | 2001-06-21 | 2003-07-03 | Wakefield Lalage M. | Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta |
JP4564261B2 (en) * | 2002-01-22 | 2010-10-20 | ジェンザイム、コーポレーション | Use of TGF-β antagonists for the treatment and prevention of chronic graft rejection |
CA2484994C (en) * | 2002-04-29 | 2016-06-14 | St. Louis University | Peptide antagonists of tgf-beta family members and therapeutic uses thereof |
US20040028661A1 (en) * | 2002-08-07 | 2004-02-12 | Bartelmez Stephen H. | Expansion of cells using thrombopoietin and anti-transforming growth factor-beta |
US20040128924A1 (en) * | 2002-08-20 | 2004-07-08 | Kobrehel Michael D. | Glazing panel installation structure and method |
US20060021290A1 (en) * | 2002-08-20 | 2006-02-02 | Kobrehel Michael D | Sacrificial shield for a window assembly |
ATE496066T1 (en) * | 2002-10-25 | 2011-02-15 | Us Gov Health & Human Serv | METHOD FOR PREVENTING TUMOR RECURRENCE BY BLOCKING TGF-BETA |
EP2365001A3 (en) * | 2003-05-01 | 2012-03-28 | Imclone LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
CA2525647A1 (en) | 2003-05-16 | 2005-02-24 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
US7381409B2 (en) | 2003-06-16 | 2008-06-03 | Celltech R&D, Inc. | Antibodies specific for sclerostin and methods of screening and use therefor |
US7209720B2 (en) * | 2003-08-26 | 2007-04-24 | Freescale Semiconductor, Inc. | Multiband and multimode transmitter and method |
US20060063208A1 (en) | 2004-08-02 | 2006-03-23 | Woolf Clifford J | DRG11-responsive (DRAGON) gene and uses thereof |
AU2005273968A1 (en) * | 2004-08-09 | 2006-02-23 | Alios Biopharma Inc. | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
US20090004182A1 (en) * | 2004-10-13 | 2009-01-01 | The Ohio State University Research Foundation | Methods to Treat or Prevent Viral-Associated Lymphoproliferative Disorders |
US7723486B2 (en) * | 2005-02-08 | 2010-05-25 | Optein, Inc. | Antibodies to TGF-β |
EP1858541B1 (en) | 2005-02-16 | 2012-07-25 | The General Hospital Corporation | Use of bmp antagonists to regulate hepcidin-mediated iron metabolism and treat iron deficiency |
CA2598090A1 (en) * | 2005-02-17 | 2006-08-24 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Synergistic effect of tgf-beta blockade and immunogenic agents on tumors |
KR100657935B1 (en) * | 2005-03-08 | 2006-12-14 | 메디제네스(주) | Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising an Antibody against TGF-? |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
ES2452115T3 (en) | 2005-06-17 | 2014-03-31 | Imclone Llc | An anti-PDGFRalpha antibody for use in the treatment of metastatic bone cancer |
WO2007050793A2 (en) | 2005-10-25 | 2007-05-03 | The Johns Hopkins University | Methods and compositions for the treatment of marfan syndrome and associated disorders |
CN101346394B (en) | 2005-12-23 | 2012-07-25 | 伊莱利利公司 | TGF-beta binding compositions |
JP5198289B2 (en) * | 2006-02-03 | 2013-05-15 | イムクローン・リミテッド・ライアビリティ・カンパニー | IGF-IR antagonists as adjuvants for the treatment of prostate cancer |
EP2230252A1 (en) | 2006-03-13 | 2010-09-22 | The Johns Hopkins University | Augmentation of endothelial thromboresistance |
EP2918288B1 (en) * | 2006-10-03 | 2017-08-16 | Genzyme Corporation | Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
WO2008124768A1 (en) | 2007-04-09 | 2008-10-16 | The General Hospital Corporation | Hemojuvelin fusion proteins and uses thereof |
EP2171062A1 (en) * | 2007-06-15 | 2010-04-07 | Genzyme Corporation | Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor |
CA2699454C (en) * | 2007-08-27 | 2012-07-24 | Auxagen, Inc. | Methods for inhibiting tgf-.beta. |
CL2008002775A1 (en) | 2007-09-17 | 2008-11-07 | Amgen Inc | Use of a sclerostin binding agent to inhibit bone resorption. |
EP2341913B1 (en) * | 2008-09-16 | 2014-11-19 | Saint Louis University | Method of enhancing tgf-beta signalling |
EP3939617A1 (en) | 2009-02-13 | 2022-01-19 | Immunomedics, Inc. | Conjugates with an intracellularly-cleavable linkage |
US20120294868A1 (en) | 2009-04-24 | 2012-11-22 | Edwards James R | Anti-tgf-beta induction of bone cell function and bone growth |
CA2774260C (en) | 2009-09-16 | 2018-10-09 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
IN2012DN03354A (en) | 2009-12-02 | 2015-10-23 | Immunomedics Inc | |
ES2584433T3 (en) | 2010-03-12 | 2016-09-27 | Genzyme Corporation | Combination therapy to treat breast cancer |
US20130195800A1 (en) | 2010-03-23 | 2013-08-01 | Intrexon Corporation | Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof |
PT2569010T (en) | 2010-05-14 | 2017-05-31 | Amgen Inc | High concentration antibody formulations |
WO2012030394A1 (en) | 2010-09-01 | 2012-03-08 | Genzyme Corporation | Treatment of myocardial infarction using tgf - beta antagonists |
JP5886212B2 (en) | 2010-12-27 | 2016-03-16 | Lsipファンド運営合同会社 | iPS cells and production method thereof |
EP2681242B1 (en) | 2011-03-01 | 2018-01-24 | Amgen Inc. | Sclerostin and dkk-1 bispecific binding agents |
EA029956B1 (en) | 2011-03-25 | 2018-06-29 | Эмджен Инк. | Anti-sclerostin antibody crystals and formulations thereof |
CN107115526A (en) | 2011-05-02 | 2017-09-01 | 免疫医疗公司 | The ultrafiltration concentration of the antibody for the allograft selection applied for small size |
EP2714735B1 (en) | 2011-06-03 | 2021-07-21 | XOMA Technology Ltd. | Antibodies specific for tgf-beta |
US20140308275A1 (en) | 2011-07-27 | 2014-10-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Methods for diagnosing and treating myhre syndrome |
DK2739311T3 (en) | 2011-08-04 | 2018-04-23 | Amgen Inc | Method of treating bone slit defects |
AU2011379972B2 (en) | 2011-10-26 | 2016-05-12 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
EP3553169B1 (en) | 2011-12-28 | 2021-11-03 | Kyoto Prefectural Public University Corporation | Normalization of culture of corneal endothelial cells |
CN107126560A (en) | 2011-12-28 | 2017-09-05 | 安进公司 | The method that alveolus bone loss is treated by using anti-osteosclerosis protein antibodies |
US9518112B2 (en) | 2012-03-08 | 2016-12-13 | Ludwig Institute For Cancer Research Ltd | TGF-β1 specific antibodies and methods and uses thereof |
WO2014006100A1 (en) | 2012-07-05 | 2014-01-09 | Ucb Pharma S.A. | Treatment for bone diseases |
CA2874864C (en) | 2012-08-14 | 2023-02-21 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
UY35148A (en) | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
CA2884313C (en) | 2012-12-13 | 2023-01-03 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
PL2971048T3 (en) | 2013-03-11 | 2019-05-31 | Genzyme Corp | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
EP4056677A1 (en) | 2013-03-14 | 2022-09-14 | The Brigham & Women's Hospital, Inc. | Compositions and methods for epithelial stem cell expansion and culture |
AU2014308751B2 (en) | 2013-08-22 | 2020-03-05 | Acceleron Pharma, Inc. | TGF-beta receptor type II variants and uses thereof |
RU2712967C2 (en) | 2013-10-31 | 2020-02-03 | Киото Прифекчурал Паблик Юниверсити Корпорэйшн | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
MX2016010683A (en) | 2014-02-21 | 2017-05-11 | Ibc Pharmaceuticals Inc | Disease therapy by inducing immune response to trop-2 expressing cells. |
CA2935748A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
CA2953567C (en) | 2014-06-24 | 2023-09-05 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
CN107073042A (en) | 2014-09-03 | 2017-08-18 | 布里格海姆妇女医院公司 | Composition, the system and method for hearing loss are treated for producing inner ear hair cells |
CN106999517A (en) | 2014-10-07 | 2017-08-01 | 免疫医疗公司 | The new adjuvant purposes of antibody drug conjugate |
MA41142A (en) | 2014-12-12 | 2017-10-17 | Amgen Inc | ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL |
ES2820768T3 (en) | 2015-04-03 | 2021-04-22 | Xoma Technology Ltd | Cancer treatment using TGF-beta and PD-1 inhibitors |
CN107428837A (en) | 2015-04-22 | 2017-12-01 | 免疫医疗公司 | Circulate separation, detection, diagnosis and/or the identification of the positive cancer cells of TROP 2 |
US10882903B2 (en) | 2015-05-18 | 2021-01-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating an alphavirus infection |
US10723793B2 (en) | 2015-06-12 | 2020-07-28 | Ludwig Institute For Cancer Research, Ltd. | TGF-β3 specific antibodies and methods and uses thereof |
PL3313443T3 (en) | 2015-06-25 | 2023-11-06 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
EP3313420B1 (en) | 2015-06-25 | 2024-03-13 | The Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
EP3316885B1 (en) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
CN108348578B (en) | 2015-08-04 | 2022-08-09 | 阿塞勒隆制药公司 | Methods for treating myeloproliferative disorders |
EP3400286A1 (en) | 2016-01-08 | 2018-11-14 | Massachusetts Institute Of Technology | Production of differentiated enteroendocrine cells and insulin producing cells |
US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
RU2018131123A (en) * | 2016-02-17 | 2020-03-17 | Новартис Аг | ANTIBODIES TO TGF-BETA2 |
US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
EP3429603B1 (en) | 2016-03-15 | 2021-12-29 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
AU2017268234A1 (en) | 2016-05-17 | 2018-12-13 | Genentech, Inc. | Stromal gene signatures for diagnosis and use in immunotherapy |
CN110392686A (en) | 2016-12-30 | 2019-10-29 | 频率治疗公司 | 1H- pyrrole-2,5-diones compound and making be used to induction it is dry/method of ancestral's sertoli cell self-renewing |
AR110755A1 (en) | 2017-01-20 | 2019-05-02 | Genzyme Corp | BONE DIRECTED ANTIBODIES |
TWI787230B (en) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | Anti-tgf-beta antibodies and their use |
ES2948647T3 (en) | 2017-05-04 | 2023-09-15 | Acceleron Pharma Inc | TGF-beta type II receptor fusion proteins and uses thereof |
MX2020004567A (en) | 2017-11-06 | 2020-08-13 | Genentech Inc | Diagnostic and therapeutic methods for cancer. |
EP3768267A4 (en) | 2018-03-20 | 2022-04-20 | Icahn School of Medicine at Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
MX2020010092A (en) | 2018-03-30 | 2020-10-28 | Amgen Inc | C-terminal antibody variants. |
WO2019236766A1 (en) | 2018-06-06 | 2019-12-12 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
EP3837351A1 (en) | 2018-08-17 | 2021-06-23 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
JP2021533788A (en) | 2018-08-17 | 2021-12-09 | フリークエンシー セラピューティクス インコーポレイテッド | Compositions and Methods for Generating Hair Cells by Up-Controlling JAG-1 |
EP3877055A1 (en) | 2018-11-05 | 2021-09-15 | Ludwig Institute for Cancer Research Ltd | Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof |
AU2019374496A1 (en) | 2018-11-05 | 2021-05-27 | Centre Hospitalier Universitaire Vaudois | Humanized and variant TGF-β3 specific antibodies and methods and uses thereof |
US20220162182A1 (en) | 2018-12-31 | 2022-05-26 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
US20220177978A1 (en) | 2019-04-02 | 2022-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
WO2021021991A1 (en) | 2019-08-01 | 2021-02-04 | Vaccinex,Inc. | Combined inhibition of semaphorin-4d and tgfb and compositions therefor |
CN113563473A (en) | 2020-04-29 | 2021-10-29 | 三生国健药业(上海)股份有限公司 | Tetravalent bispecific antibody, preparation method and application thereof |
EP4251645A1 (en) | 2020-11-25 | 2023-10-04 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
EP4342497A1 (en) | 2021-05-10 | 2024-03-27 | Kawasaki Institute of Industrial Promotion | Antibody having reduced binding affinity for antigen |
US20230144192A1 (en) | 2021-11-01 | 2023-05-11 | Genzyme Corporation | Treatment of osteogenesis imperfecta |
WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3588058T3 (en) * | 1984-07-16 | 2005-04-07 | Celtrix Pharmaceuticals, Inc., Palo Alto | Cartilage-inducing polypeptide factors from bone |
US5262319A (en) * | 1985-04-19 | 1993-11-16 | Oncogene Science, Inc. | Method for obtaining bone marrow free of tumor cells using transforming growth factor β3 |
US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US5622853A (en) * | 1990-05-01 | 1997-04-22 | Becton Dickinson And Company | T lymphocyte precursor |
IL98569A0 (en) * | 1990-06-20 | 1992-07-15 | Bristol Myers Squibb Co | Pharmaceutical compositions containing tgf-b and antagonists thereof for modulating blood pressure |
GB9106678D0 (en) * | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
DE69233254T2 (en) * | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanized Heregulin antibody |
JPH08504763A (en) * | 1992-10-29 | 1996-05-21 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | Use of TGF-β receptor fragment as a therapeutic agent |
CA2155515A1 (en) * | 1993-02-19 | 1994-09-01 | Wendy Waegell | Expansion of stem cells in long term bone marrow cultures by neutralization of tgf-.beta. |
-
1991
- 1991-09-06 US US07/759,109 patent/US5571714A/en not_active Expired - Lifetime
-
1995
- 1995-05-04 US US08/434,976 patent/US5772998A/en not_active Expired - Lifetime
- 1995-05-04 US US08/434,977 patent/US5783185A/en not_active Expired - Lifetime
-
1998
- 1998-06-15 US US09/097,843 patent/US6090383A/en not_active Expired - Lifetime
-
2000
- 2000-03-21 US US09/531,383 patent/US6419928B1/en not_active Expired - Fee Related
-
2002
- 2002-06-17 US US10/173,074 patent/US20020176858A1/en not_active Abandoned
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005097832A3 (en) * | 2004-03-31 | 2005-12-01 | Genentech Inc | Humanized anti-tgf-beta antibodies |
US7527791B2 (en) | 2004-03-31 | 2009-05-05 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
US8012482B2 (en) | 2004-03-31 | 2011-09-06 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
WO2019077037A1 (en) | 2017-10-18 | 2019-04-25 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Methods and compounds for improved immune cell therapy |
WO2021202320A1 (en) * | 2020-03-30 | 2021-10-07 | Yale University | Methods for treating inflammatory and fibrotic diseases and disorders |
Also Published As
Publication number | Publication date |
---|---|
US6419928B1 (en) | 2002-07-16 |
US5571714A (en) | 1996-11-05 |
US5772998A (en) | 1998-06-30 |
US5783185A (en) | 1998-07-21 |
US6090383A (en) | 2000-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6419928B1 (en) | Monoclonal antibodies to transforming growth factor-beta and methods of use | |
Dasch et al. | Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. | |
KR900004420B1 (en) | Antibody for interleukin-1 | |
US7227004B2 (en) | Antibodies to vascular endothelial cell growth factor | |
EP0783893B1 (en) | Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient | |
EP1238986B1 (en) | Use of Vascular endothelial cell growth factor antagonists | |
FI104180B (en) | A method of preparing a composition for treating conditions mediated by an antibody to IL-4 polypeptide | |
EP0364778B1 (en) | Antibody against interleukin-1beta | |
JP2005510212A (en) | Antibody inhibitors of GDF-8 and uses thereof | |
JP3392860B2 (en) | Anti-idiotype antibodies that induce an immune response to glycosphingolipids and uses thereof | |
Sheppard et al. | Production and characterization of monoclonal antibodies to tetanus toxin | |
Kasahara et al. | Preparation and characterization of polyclonal and monoclonal antibodies against human interleukin 1 alpha (IL 1 alpha). | |
EP0396505A2 (en) | Monoclonal antibodies specific for an immunoglobulin isotype | |
CA2058041A1 (en) | Anti-igf-ii monoclonal antibody | |
BAETS et al. | Monoclonal antibodies to human thyroglobulin as probes for thyroglobulin structure | |
Ziltener et al. | Monoclonal antipeptide antibodies recognize IL-3 and neutralize its bioactivity in vivo. | |
AU618024B2 (en) | Antibodies to angiogenin: immunotherapeutic agents | |
EP0450472B1 (en) | Monoclonal antibodies that inhibit growth of kaposi's sarcoma | |
TAHARA et al. | Synthetic peptide-generated monoclonal antibodies to transforming growth factor-β1 | |
JPH10114680A (en) | Carcinostatic agent | |
JP2871743B2 (en) | Monoclonal antibodies and hybridomas secreting the antibodies | |
JPH04120025A (en) | Enhancer of interleukin-6 action | |
EP0406880A2 (en) | Method for stimulating macrophage activity against tumors and composition therefor | |
JPH11302193A (en) | Vascularization inhibitor | |
JPH1149701A (en) | Anticancer agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |